Jan Christop L. Merene

Array ( [id] => 9537156 [patent_doc_number] => 20140161803 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-12 [patent_title] => 'CONSTITUTIVELY ACTIVE UPAR VARIANTS AND THEIR USE FOR THE GENERATION AND ISOLATION OF INHIBITORY ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/233844 [patent_app_country] => US [patent_app_date] => 2012-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 24061 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14233844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11319382 [patent_doc_number] => 09518120 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-12-13 [patent_title] => 'Anti-CXCR4 antibody and its use for the detection and diagnosis of cancer' [patent_app_type] => utility [patent_app_number] => 14/235274 [patent_app_country] => US [patent_app_date] => 2012-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 13 [patent_no_of_words] => 18174 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14235274 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9546029 [patent_doc_number] => 20140170677 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-19 [patent_title] => 'USE OF THE ANTIBODY I-3859 FOR THE DETECTION AND DIAGNOSIS OF CANCER' [patent_app_type] => utility [patent_app_number] => 14/235235 [patent_app_country] => US [patent_app_date] => 2012-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 16320 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14235235 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8875593 [patent_doc_number] => 08470557 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-06-25 [patent_title] => 'Isolated nucleic acids encoding activated factor V and methods for production thereof' [patent_app_type] => utility [patent_app_number] => 13/557882 [patent_app_country] => US [patent_app_date] => 2012-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 12644 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 234 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13557882 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10911767 [patent_doc_number] => 20140314784 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-23 [patent_title] => 'ANTI-CXCR4 ANTIBODIES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/232751 [patent_app_country] => US [patent_app_date] => 2012-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 52826 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14232751 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8670952 [patent_doc_number] => 20130045491 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-02-21 [patent_title] => 'METHODS FOR ACTIVATING T CELLS' [patent_app_type] => utility [patent_app_number] => 13/551707 [patent_app_country] => US [patent_app_date] => 2012-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 19769 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13551707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8892149 [patent_doc_number] => 20130165332 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-27 [patent_title] => 'COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES' [patent_app_type] => utility [patent_app_number] => 13/549297 [patent_app_country] => US [patent_app_date] => 2012-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42833 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13549297 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9448937 [patent_doc_number] => 20140120106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-01 [patent_title] => 'Stimulation of Arterial Collateral Growth and Lymphogenesis' [patent_app_type] => utility [patent_app_number] => 14/131163 [patent_app_country] => US [patent_app_date] => 2012-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 25460 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14131163 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9476722 [patent_doc_number] => 20140134185 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-15 [patent_title] => 'Composition Comprising Inhibitors of IRS-1 and of VEGF' [patent_app_type] => utility [patent_app_number] => 14/130246 [patent_app_country] => US [patent_app_date] => 2012-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 11174 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14130246 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8875592 [patent_doc_number] => 08470556 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-06-25 [patent_title] => 'Nucleic acids that encode antigen binding proteins that bind PAR-2' [patent_app_type] => utility [patent_app_number] => 13/532242 [patent_app_country] => US [patent_app_date] => 2012-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 4 [patent_no_of_words] => 24209 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13532242 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9739768 [patent_doc_number] => 20140275487 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-18 [patent_title] => 'BINDING DOMAINS DIRECTED AGAINST GPCR:G PROTEIN COMPLEXES AND USES DERIVED THEREOF' [patent_app_type] => utility [patent_app_number] => 14/129100 [patent_app_country] => US [patent_app_date] => 2012-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 43612 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14129100 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9254642 [patent_doc_number] => 08618058 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-12-31 [patent_title] => 'Peptide composition for cancer treatment by inhibiting TRPV6 calcium channel activity' [patent_app_type] => utility [patent_app_number] => 13/526045 [patent_app_country] => US [patent_app_date] => 2012-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 17 [patent_no_of_words] => 21670 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13526045 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8465062 [patent_doc_number] => 20120270230 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-25 [patent_title] => 'MUTANT G-PROTEIN COUPLED RECEPTORS AND METHODS FOR SELECTING THEM' [patent_app_type] => utility [patent_app_number] => 13/493898 [patent_app_country] => US [patent_app_date] => 2012-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 27270 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13493898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9737297 [patent_doc_number] => 20140273015 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-18 [patent_title] => 'BINDING COMPOUNDS TO HUMAN Beta 1-ADRENORECEPTOR (Beta 1-AR) AND THEIR USE IN MEASUREMENT OF AUTO-ANTI- Beta 1-AR ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/124649 [patent_app_country] => US [patent_app_date] => 2012-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 33393 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14124649 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8465869 [patent_doc_number] => 20120271037 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-25 [patent_title] => 'PRODUCTION AND PURIFICATION OF IL-29' [patent_app_type] => utility [patent_app_number] => 13/488840 [patent_app_country] => US [patent_app_date] => 2012-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36809 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13488840 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8566485 [patent_doc_number] => 20120329056 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-12-27 [patent_title] => 'METHODS OF EVALUATING RELAPSE RISK OF ACUTE MYELOID LEUKEMIA USING NUCLEIC ACIDS OR FRAGMENTS ENCODING FLT3 KINASE' [patent_app_type] => utility [patent_app_number] => 13/486826 [patent_app_country] => US [patent_app_date] => 2012-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 7063 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13486826 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10635692 [patent_doc_number] => 09353186 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-31 [patent_title] => 'Neutralizing prolactin receptor antibody Mat3 and its therapeutic use' [patent_app_type] => utility [patent_app_number] => 14/123517 [patent_app_country] => US [patent_app_date] => 2012-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 21 [patent_no_of_words] => 24922 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14123517 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8780520 [patent_doc_number] => 20130102495 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-04-25 [patent_title] => 'Sperm-Specific Cation Channel, Catsper1 and Uses Therefor' [patent_app_type] => utility [patent_app_number] => 13/484061 [patent_app_country] => US [patent_app_date] => 2012-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 23283 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13484061 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11536923 [patent_doc_number] => 09611321 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-04-04 [patent_title] => 'Rationally-designed anti-mullerian inhibiting substance type II receptor antibodies' [patent_app_type] => utility [patent_app_number] => 14/122286 [patent_app_country] => US [patent_app_date] => 2012-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 8158 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14122286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8501987 [patent_doc_number] => 20120301394 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-29 [patent_title] => 'TARGETING AND IN VIVO IMAGING OF TUMOR-ASSOCIATED MACROPHAGES' [patent_app_type] => utility [patent_app_number] => 13/480350 [patent_app_country] => US [patent_app_date] => 2012-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 30959 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13480350 [rel_patent_id] =>[rel_patent_doc_number] =>)